Condition (MeSH)
Carcinoma, Ductal, Breast
ClinicalTrials.gov lists 86 trials for Carcinoma, Ductal, Breast or a narrower condition beneath it. Intarcia Therapeutics has the most among industry and government lead sponsors, with 3.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
86 of the 86 trials are tagged with Carcinoma, Ductal, Breast itself; the rest are tagged with a narrower condition beneath it.
When did Carcinoma, Ductal, Breast trials start? (26)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 8
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2023 | 2 |
| 2022 | 1 |
| 2021 | 2 |
| 2020 | 2 |
| 2019 | 5 |
| 2018 | 4 |
| 2017 | 5 |
| 2016 | 3 |
| 2015 | 1 |
Showing 10 of 26 earlier years.
No forecast is made for this condition: it averages 0.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 4 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Carcinoma, Ductal, Breast trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 10 |
| Phase 1/2 | 4 |
| Phase 2 | 20 |
| Phase 2/3 | 2 |
| Phase 3 | 16 |
| Phase 4 | 2 |
| Not applicable | 23 |
| Observational | 9 |
How many Carcinoma, Ductal, Breast trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 6 |
| Active, not recruiting | 6 |
| Completed | 48 |
| Terminated | 9 |
| Withdrawn | 5 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Carcinoma, Ductal, Breast trials? (6)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Intarcia Therapeutics | 3 |
| Eastern Cooperative Oncology Group | 2 |
| G1 Therapeutics, Inc. | 2 |
| NSABP Foundation Inc | 2 |
| Radiation Therapy Oncology Group | 2 |
Showing 5 of 6 sponsors.
Which drugs are being tested for Carcinoma, Ductal, Breast? (6)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| (nab)-paclitaxel | 9 |
| Cytoxan | 7 |
| TRASTUZUMAB | 5 |
| Atamestane | 3 |
| Toremifene | 3 |
Showing 5 of 6 drugs.
Interventions as named in the registry (9)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| or carboplatin | 8 |
| Letrozol (Femara, Novartis) | 7 |
| Radiation Therapy | 7 |
| Adjuvant Therapy | 5 |
| Brachytherapy | 4 |
Showing 5 of 9 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Carcinoma, Ductal, Breast trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Skin infection | 13 | 3 |
| Breast infection | 12 | 1 |
| Fatigue | 12 | 3 |
| Chest wall pain | 10 | 1 |
| Dermatitis radiation | 10 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Carcinoma, Ductal, Breast? (574)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Time-Restricted Eating and Metformin in Invasive Breast Cancer or DCIS: A Randomized, Phase IIb, Presurgical Trial. Preliminary Safety Analysis. | Cancer prevention research (Philadelphia, Pa.) | 2026 | Yes |
| Breast Cancer Recurrence after Cryoablation in Patients Who Are Poor Surgical Candidates or Who Refuse Surgery. | Journal of vascular and interventional radiology : JVIR | 2025 | Yes |
| NOVEMBER, A Phase 2 Trial of a 9-Day Course of Whole Breast Radiation Therapy With a Simultaneous Lumpectomy Boost for Early-Stage Breast Cancer. | International journal of radiation oncology, biology, physics | 2025 | Yes |
| Breast Tumor-Bed Biopsy for Pathological Complete Response Prediction: The NRG-BR005 Nonrandomized Clinical Trial. | JAMA surgery | 2025 | Yes |
| Preoperative Radiation Boost Results in Low Rates of Re-excision and Reduced Locoregional Treatment Time in Breast Cancer Patients. | Annals of surgical oncology | 2025 | Yes |
Showing 5 of 574 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.